share_log

Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

阿格斯研究維持對Regeneron Pharmicals的買入,將目標股價上調至920美元
Benzinga ·  2023/09/15 11:03

Argus Research analyst Jasper Hellweg maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $825 to $920.

Argus Research分析師Jasper Hellweg維持Regeneron製藥公司(納斯達克代碼:REGN)的買入,並將目標價從825美元上調至920美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論